Exploring SGLT2 Inhibitors' Activity in Breast Cancer: An Overview
Abstract
Sodium‒glucose cotransporter 2 (SGLT2) inhibitors have become viable therapeutic options for treating breast cancer. Diabetes is the primary source of these medications. This research examines how SGLT2 blockers can induce apoptosis, decrease the amount of glucose taken up by cancer cells, and modify key signaling pathways, such as the PI3K/AKT/mTOR and MAPK pathways. The effects of four different SGLT2 inhibitors on breast cancer cells were investigated in this study via both in vitro and in vivo testing: dapagliflozin, ipragliflozin, canagliflozin, and empagliflozin. The potential synergistic effects of these inhibitors with conventional chemotherapy medications were also examined. This review explores the complex relationship between SGLT2 inhibitors and breast cancer, examining how drugs interact with this disease at various stages of its development. Additionally, this study highlights how SGLT2 inhibitors may be used in conjunction with precision medicine techniques to treat breast cancer. Although encouraging outcomes have been noted, this review highlights the necessity of additional clinical studies to evaluate the safety and effectiveness of SGLT2 blockers in patients with breast cancer, in addition to ongoing research into the molecular mechanisms underlying the anticancer effects of these drugs.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.